2017 Research Awards
The 2017 Premier's Awards for Outstanding Cancer Research were held on 3 November at the Four Seasons, Sydney.
Find out about the winners and discover their achievements in cancer research.
- Outstanding Cancer Researcher of the Year Award
- Professor Rob Sutherland AO Make A Difference Award
- Excellence in Translational Cancer Research Award
- Outstanding Cancer Clinical Trials Unit Award
- Wildfire Highly Cited Publication Award
- Rising Star PhD Candidate Award
- Outstanding Cancer Research Fellow Award
- Image gallery
2017 award recipients
Outstanding Cancer Researcher of the Year Award
Professor Richard Kefford AM
Professor Richard Kefford is a world-leading researcher and clinician in the causes and treatment of melanoma.
His achievements have revolutionised the understanding of cancer biology and drastically improved therapies for people living with melanomas over the course of 30 years.
Professor Kefford has been a Principal Investigator on over 40 clinical trials exploring new immunotherapies that are transforming the treatment of melanoma.
Professor David Goldstein
Professor David Goldstein is a leading researcher and clinician in the field of pancreatic cancer.
His laboratory research has informed contemporary understanding of how the disease develops and spreads.
Professor Goldstein has been instrumental in raising the profile of pancreatic cancer within the medical, surgical and radiation oncology professions and the public.
Professor Richard Scolyer and Professor Georgina Long – Melanoma Institute Australia
The work of Professors Richard Scolyer and Georgina Long is leading to major innovations and advances in melanoma prevention, diagnosis and treatment.
With the team at Melanoma Institute Australia, they have made key discoveries and transformed care for people with melanoma – from early stage disease to those with advanced stage disease.
Central West Cancer Care Centre
Central West Cancer Centre in the Western NSW LHD has doubled the number of cancer clinical trials open for recruitment.
It has also seen a 60 per cent increase in the recruitment of cancer patients to interventional cancer clinical trials.
Professor Helen Rizos – Melanoma Translational Research Team
Professor Rizos’ study is the first and largest to document the mechanisms of resistance in a large cohort of melanoma patients treated with the BRAF inhibitor dabrafenib.
It has had 124 citations since publication on 1 April, 2014.
Title: BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Res 20, 1965-1977. see abstract and full text pdf
Rebecca Poulos’ PhD research uses ‘big data’ to study DNA mutation and repair processes in regulatory regions of cancer genomes.
Her research output includes seven first-author publications, including publications in the journals ‘Nature’ and ‘Cell Reports’, together with a review article, invited editorial and invited book chapter.
Dr Marina Pajic
Dr Marina Pajic has been awarded two Career Development Fellowships from the Cancer Institute NSW for research into pancreatic cancer.
As part of the International Cancer Genome Consortium sequencing effort, Dr Pajic has established a unique personalised medicine project for pancreatic cancer, and leads the Personalised Cancer Therapeutics Group at the Garvan Institute for Medical Research.